This morning heralds the long awaited ODAC meeting for AstraZeneca’s oral SERD, camizestrant, for the treatment of HR+ HER2- breast…
Follow Biotechstrategyblog's news and updates in a matter of seconds! We will deliver any update via email, phone or you can read them from here on the site on your own news page.
You can even combine different feeds with the feed for Biotechstrategyblog.
Subscribing and unsubscribing is fast, easy and risk free.
The whole service is free of cost.
Biotechstrategyblog: Biotech Strategy Blog Cancer Conferences New Products